You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Now your patients can get proven cardiac pacing care with MRI access. Revo MRI is specifically engineered for MRI safety – the first MRI pacing system FDA-approved for use with MRI.
The Revo MRI SureScan pacing system is MR Conditional allowing patients to undergo MRI under the specified conditions for use. A complete system, consisting of a Medtronic Revo MRI SureScan IPG implanted with two SureScan leads, is required for use in the MRI environment.
It is estimated that up to 75% of pacemaker patients will have a medical need for an MRI over the lifetime of their device.1
Elderly patients are the primary users of MRI. Individuals over age 65 are twice as likely to need an MRI compared to younger patients.2
The potential need for a pacemaker also increases with age.
Medical and surgical specialties rely on MRI for diagnosis. In fact, MRI is the gold standard diagnostic tool for soft tissue imaging for neurologists, oncologists, and orthopaedic surgeons. Your pacemaker choice today can affect their decisions and diagnostic capabilities tomorrow.
The prevalence of common comorbidities increases over age 65,3-5 often requiring MRI – the same population most likely to require a pacemaker.
The Revo MRI Pacing System with SureScan® technology has met the rigors of clinical evaluation, regulatory review, and FDA approval.
Multiple safety features were designed and incorporated from the ground up:
The two available SureScan lead options:
Over 3.2 M 5076 leads have been sold worldwide with over 97.6% reliability at 10 years.6
Managed Ventricular Pacing (MVP) is exclusive to Medtronic devices. It is the only mode-switching technology that reduces unnecessary RV pacing by 99%.1
MINERVA Results Summary1
Multicenter (63 centers) international, randomized single blind study with 3 arms enrolling 1,166 patients with:
49% relative reduction (p = 0.001) in cardioversions
for atrial arrhythmias between DDDRP + MVP and
52% relative reduction (p < 0.0001) in AF-related
hospitalizations and ER visits between DDDRP + MVP
and Control DDDR
Potential Contribution of Reactive ATP®
Risk of AF > 7 days and aATP efficacy
Boriani G, et al. Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial. Eur Heart J. Published online April 25, 2014.
|Revo MRI SureScan Pacemaker|
|Body||6.1 Fr||7 Fr|
|Recommended Introducer Size||9 Fr with guidewire
7 Fr without guidewire
|11 Fr with guidewire
8 Fr without guidewire
|Standard Lengths||35, 45, 52, 58, 65, 85 cm||45, 52, 58 cm|
Kalin R, Stanton MS. Current clinical issues for MRI scanning of pacemaker and defibrillator patients. PACE. April 2005;28(4):326-328.
Global Industry Analysts, Inc. Magnetic Resonance Imaging (MRI) Equipment – A Global Strategic Business Report. San Jose, CA. 2002.
National Cancer Institute. April 2009. US estimated complete prevalence (including counts) by age on 1/1/2006. Based on November 2008 SEER data submission; DCCPS, Surveillance Research Program, Statistical Research and Applications Branch.
Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. May 1998;41(5):778-799.
American Heart Association. Heart Disease and Stroke Statistics – 2010 Update: Learn and Live. Prevalence of stroke by age and sex (NHANES: 2003-2006).
DeBus, Becky. Model 5076 Lead Survival Function Calculation. August 2014. Medtronic Data On File.
Gillis AM, Pürerfellner H, Israel CW, et al. Reduction of unnecessary ventricular pacing due to the Managed Ventricular Pacing (MVP) mode in pacemaker patients: benefit for both sinus node disease and AV block indications. Heart Rhythm. 2005;Abstract B21-1.